Results 81 to 90 of about 956,320 (295)

Psychological and Neurodevelopmental Correlates of Extreme Demand Avoidance in a Clinical Sample, an Exploratory Study

open access: yesAutism Research, EarlyView.
ABSTRACT Extreme/pathological demand avoidance (EDA) is a behavioral profile characterized by the avoidance of everyday demands, with significant impact on the individuals and those around them. Little is understood regarding the correlates and drivers of EDA; understanding these better may lead to targeted interventions and support strategies.
Oliver Lack   +6 more
wiley   +1 more source

Neurotic disorders and the receipt of psychiatric treatment [PDF]

open access: yes, 2000
Background. Access to psychiatric treatment by people with neurotic disorders in the general population is likely to be affected both by the severity of disorder and by sociodemographic differences.Method.
Lewis, G   +8 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

SUICIDE MORTALITY IN NON-AFFECTIVE PSYCHOTIC DISORDERS: NATIONWIDE EVIDENCE ON RISK FACTORS AND TEMPORAL PATTERNS [PDF]

open access: yesPsychiatria Fennica
Individuals with non-affective psychotic disorders experience substantially higher suicide mortality than the general population, particularly during the early stages of illness.
MINNA HOLM, JAANA SUVISAARI, TEEMU VAUHKONEN, MAIJA LINDGREN, EMMI LIUKKO, LAURA SCHILDT, KIMMO SUOKAS, TIMO PARTONEN
doaj  

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask   +6 more
wiley   +1 more source

The Evolution of Psychiatric Epidemiology: Where to Next? [PDF]

open access: yesCan J Psychiatry, 2021
Plana-Ripoll O   +3 more
europepmc   +1 more source

When meta‐analyses mislead: Promises and pitfalls in teratology counselling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Meta‐analysis has become a central tool for evidence synthesis in clinical teratology, offering the promise of increased statistical power, earlier signal detection and consolidated guidance for teratology counselling. When conducted rigorously and interpreted carefully, pooled analyses can provide clinicians with a structured basis for risk ...
Yusuf Cem Kaplan, Nusret Uysal
wiley   +1 more source

Mental and Substance Use Disorders Prevalence Study: Background and Methods

open access: yesInternational Journal of Methods in Psychiatric Research
Objective The Mental and Substance Use Disorders Prevalence Study (MDPS) builds upon previous epidemiologic studies to provide estimates of prevalence and treatment rates of mental and substance use disorders among adults aged 18–65 in the U.S. The study
Heidi Guyer   +23 more
doaj   +1 more source

A scoping review of adverse events associated with concomitant beta‐adrenoreceptor blockers and selective serotonin reuptake inhibitors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Beta‐adrenoreceptor blockers (beta‐blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group.
Ziyi Cai   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy